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Abstract: Background: Adrenocortical carcinoma (ACC) is an aggressive 
malignancy with a low but variable overall survival rate. The role of 
long noncoding RNAs (lncRNAs) in ACC is poorly understood. Thus, in this 
study we performed lncRNA expression profiling in ACC, adrenocortical 
adenoma (ACA) and normal adrenal cortex (NAC). 
Methods: LncRNA expression profile, using ArrayStar Human LncRNA/mRNA 
Expression Microarray V3.0, was analyzed in 11 ACA, 9 ACC and 5 NAC 
samples. Differentially expressed lncRNAs were validated using TaqMan 
real-time quantitative PCR with additional samples. The ACC Cancer Genome 
Atlas (TCGA) project dataset was used to evaluate the prognostic utility 
of lncRNAs.  
Results: Unsupervised hierarchical clustering showed distinct clustering 
of ACC samples compared with NAC and ACA samples by lncRNA expression 
profiles. A total of 874 lncRNAs were differentially expressed between 
ACC and NAC. LINC00271 expression level was associated with  prognosis, 
patients with low LINC00271 expression survived shorter than patients 
with high LINC00271 expression. Low LINC00271 expression was positively 
associated with WNT signaling, cell cycle, and chromosome segregation 
pathways.  
Conclusions: ACC has a distinct lncRNA expression profile. LINC00271 is 
downregulated in ACC and is involved in biological pathways commonly 
dysregulated in ACC. 
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Abstract 
Background: Adrenocortical carcinoma (ACC) is an aggressive malignancy with a low but 
variable overall survival rate. The role of long noncoding RNAs (lncRNAs) in ACC is poorly 
understood. Thus, in this study we performed lncRNA expression profiling in ACC, 
adrenocortical adenoma (ACA) and normal adrenal cortex (NAC). 
Methods: LncRNA expression profile, using ArrayStar Human LncRNA/mRNA Expression 
Microarray V3.0, was analyzed in 11 ACA, 9 ACC and 5 NAC samples. Differentially expressed 
lncRNAs were validated using TaqMan real-time quantitative PCR with additional samples. The 
ACC Cancer Genome Atlas (TCGA) project dataset was used to evaluate the prognostic utility of 
lncRNAs.  
Results: Unsupervised hierarchical clustering showed distinct clustering of ACC samples 
compared with NAC and ACA samples by lncRNA expression profiles. A total of 874 lncRNAs 
were differentially expressed between ACC and NAC. LINC00271 expression level was 
associated with  prognosis, patients with low LINC00271 expression survived a significantly 
shorter time than patients with high LINC00271 expression. Low LINC00271 expression was 
positively associated with WNT signaling, cell cycle, and chromosome segregation pathways.  
Conclusions: ACC has a distinct lncRNA expression profile. LINC00271 is downregulated in 
ACC and is involved in biological pathways commonly dysregulated in ACC. 
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Introduction 
 Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with an annual 
incidence of 0.7–2.0 cases per million people and a five-year overall survival rate ranging from 
32% to 47%).
1,2
 Furthermore, even after complete tumor resection, over half of the patients 
develop recurrent disease.
3
 Patients with locally advanced and metastatic ACC often undergo 
therapy, which consists of a regimen, including adrenolytic mitotane plus combination 
chemotherapy with etoposide, doxorubicin, and cisplatin. Unfortunately, this regimen has very 
limited therapeutic benefit.
4
 The role of adjuvant therapy for ACC is controversial because of 
questionable therapeutic benefit of current agents and the heterogenous prognosis.
3
 
Understanding the mechanism behind ACC initiation and progression could help in identifying 
diagnostic and prognostic markers, and therapeutic targets.  
Several genomic studies of ACC have reported on distinct ACC genome-wide gene 
expression, micro-RNA expression, methylation and copy number alteration profiles compared 
with adrenal cortical adenomas (ACAs) and normal adrenal cortex (NAC).
5-10
 These studies have 
led to the molecular classification of ACC that is relevant for predicting prognosis. Recently, 
long noncoding RNAs (lncRNAs) have been suggested to be dysregulated in ACC.
11
 LncRNAs 
are RNA transcripts longer than 200 nucleotides that do not encode protein and are localized in 
the cell nucleus or cytoplasm.
12
 The expression of lncRNAs is more tissue specific than protein-
coding genes and they function as decoys, scaffolds and enhancer RNAs and are involved in 
chromatin remodeling, as well as transcriptional and post-transcriptional regulation.
13 
To our knowledge, the study by Glover and colleagues has been the only study that has 
investigated lncRNA expression profile in ACCs, ACAs and NAC.
11
 They reported that the 
highest number of differentially expressed lncRNAs were between ACAs and NAC, with almost 
3-fold less lncRNAs being differentially expressed between ACCs and NAC. This finding 
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suggested that changes in lncRNA expression could be an early event in the pathogenesis of both 
ACC and ACAs. However, this finding is in contrast to previous genome-wide analysis results 
that demonstrated a multistep progression in ACC, with increasing genomic changes from NAC 
to ACA to ACC.
8
 Therefore, to further our knowledge of the role of lncRNA in ACCs, we 
performed lncRNA expression profiling using lncRNA microarrays to identify differentially 
expressed lncRNAs in ACCs compared with NACs and ACAs. We also investigated whether 
lncRNA expression levels were associated with ACC overall survival times.  
 
Materials and methods 
Tissue samples 
Patients’ tumor tissues were procured after informed consent for genetic studies on an 
Institutional Review Board-approved procurement clinical protocol (NCT01005654 and 
NCT01348698). The tissues were immediately snap frozen in liquid nitrogen and stored at -80°C. 
For this study, we used 11 ACA samples and nine ACC samples. Five normal NACs were 
obtained at the time of organ donation harvesting. These 25 tissue samples were used for lncRNA 
microarray profiling. In addition to these samples, an additional 10 ACC samples were included 
in the quantitative RT-PCR (qRT-PCR) validation (Table 1). Tumors were classified as benign 
when the Weiss criteria scores were less than 3 (all the benign samples included had a Weiss 
score of 0), and tumors were classified as ACC when the Weiss criteria scores were more than or 
equal to 3.
14
 Only samples with at least 80% tumor cells were included for analysis. 
 
RNA extraction  
Total RNA was extracted from fresh frozen tissue samples using an RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. RNA quality was 
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 5 
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Englewood, CO, USA). 
Only samples with a minimum RNA integrity number of seven were included for analysis. 
 
Microarray profiling  
The ArrayStar Human LncRNA/mRNA Expression Microarray Version 3.0 (ArrayStar, 
Inc., Rockville, MD, USA) was used, which includes 30,586 lncRNA probes and 26,109 coding 
transcripts, for lncRNA profiling. RNA labeling, microarray hybridization, slide washing and 
scanning were performed based on the standard protocols of ArrayStar. Agilent Feature 
Extraction software (version 11.0.1.1) was used to analyze acquired array images. The 
microarray specifications and derived data are accessible through National Center for 
Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) accession number 
GSE124531. 
 
TaqMan real-time quantitative PCR 
RNA was reverse transcribed using the High Capacity cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA, USA). TaqMan qRT-PCR was performed using the 
7900HT fast real-time PCR systems (Applied Biosystems). The reaction contained cDNA, 
TaqMan 2×universal PCR master mix and TaqMan gene expression assays primers (Applied 
Biosystems). LncRNAs were selected for validation based on three criteria: 1) availability of 
validated TaqMan gene expression primer/probe assays, 2) possible role in cancer, and 3) 
magnitude of differential expression. The gene expression assays used were: HOTTIP 
(Hs03649396_m1), CHL1 (Hs04332026_m1), HOXA11-AS1 (Hs_03454334_g1), CRNDE 
(HS04404483_m1), LINC00271 (Hs03657384_m1), FAM211A-AS1 (Hs03678558_g1), TBXAS1 
(Hs01096058_s1) and GAPDH (Hs99999905_m1). 
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Comparative genomic hybridization (CGH) array analysis 
We used our previously published genome-wide CGH array data in a cohort of NAC, 
ACA, and ACC.
8
 The LINC100271 site was manually scanned for its copy number status using 
Nexus software.  
 
Statistical and data analysis 
LncRNA expression profiles of ACC samples were compared with NAC and ACA 
samples. The Gaussian linear model was used to calculate P-values, and false discovery rates 
(FDRs) were calculated using the Benjamini-Hochberg method for each lncRNA. LncRNAs with 
log2 fold change ≥2 and FDR <0.05 were defined as differentially expressed lncRNAs. 
Differentially expressed lncRNAs were mapped to their associated gene names and then gene set 
enrichment analysis (GSEA) was performed on these genes. An in-house R package, OmicPath 
(v 0.1) was used to perform GSEA to discover potential KEGG pathway associations for each set 
of differentially expressed lncRNAs. Pathways with a P-value < 0.05 were considered significant. 
Survival curves were plotted using the Kaplan-Meier methods, and differences in survival rates 
were determined using the log-rank test. These statistical analyses were done with GraphPad 
Software and P < 0.05 was considered significant.  
The ACC cohort from the Cancer Genome Atlas (TCGA) project database (https://tcga-
data.nci.nih.gov/tcga/) which included 79 patients with HOTTIP, CHL1, HOXA11-AS1, CRNDE, 
LINC00271, FAM211A-AS1 and TBXAS1 expression data, as well as follow-up information, were 
used to study the prognostic significance of lncRNAs. For overall survival analysis two groups 
were defined based on the lncRNA expression levels in the primary tumor. Those with a lncRNA 
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level ranked in the top half were classified into the high expression group and the rest into the 
low expression group based on the median value.  
 The gene expression profiles of ACC samples deposited in the TCGA project database 
were analyzed to compare expression patterns in tumors with high (n = 39) vs. low LINC100271 
expression (n = 40). The downloaded data consisted of quantified gene expression data, that were 
further processed using the DESeq2 package.
15
 The differentialy expressed genes were annotated, 
and GSEA analysis was performed using the clusterProfiler package.
16
  
 
Results 
Differentially expressed lncRNAs in ACC versus NAC 
Unsupervised hierarchical and heat map clustering showed distinct clustering of ACC 
samples compared with NAC and ACA samples (Fig. 1). Eight hundred and seventy-four 
lncRNAs were differentially expressed in ACC compared with NAC, of which 409 were 
upregulated and 465 were downregulated. The 874 differentially expressed lncRNAs 
corresponded to 330 annotated lncRNA genes. Among the upregulated lncRNAs, the highest 
log2 fold change was 8.5 for an unannotated lncRNA gene, and RAD50 was the highest 
upregulated annotated lncRNA gene with a log2 fold change of 6.1. Among the downregulated 
lncRNAs, the highest log2 fold change was 8.3 for an unannotated lncRNA gene and 6.4 for 
HAND2, the highest downregulated annotated lncRNA gene. One hundred and eighty-three 
differently expressed lncRNAs had established functions in cancer development and cancer 
progression. Selected carcinogenesis-related lncRNAs are summarized in Table 2.  
To test the validity of the microarray findings, seven lncRNAs (HOTTIP, CHL1, 
HOXA11-AS1, CRNDE, LINC00271, FAM211A-AS1 and TBXAS1) were selected among the 
carcinogenesis-related differentially expressed lncRNAs and their expression was analyzed by 
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 8 
TaqMan qRT-PCR. The validation cohort included 19 ACC samples and 5 NAC samples. 
HOTTIP, HOXA11-AS1 and CRNDE were overexpressed in ACC (P  < 0.05) and confirmed by 
TaqMan qRT-PCR in the validation cohort (P < 0.05; Fig. 2). LINC00271, FAM211A-AS1 and 
TBXAS1 expression was downregulated in ACC (P < 0.05) and also by TaqMan qRT-PCR (P < 
0.05) (Fig 2). The microarray result for CHL1 was not confirmed in the validation cohort. 
Upregulated expression of CHL1 was identified in the microarray analysis (P < 0.05) while 
CHL1 was found to be not significantly upregulated by TaqMan qRT-PCR in the validation 
cohort.  
 
Differentially expressed lncRNAs in ACC versus ACA 
One thousand seventy-six lncRNAs were differentially expressed in ACC compared with 
ACA, of which 780 were upregulated and 296 were downregulated. The 1,076 differentially 
expressed lncRNAs corresponded to 376 annotated lncRNA genes. Among the upregulated 
lncRNAs, the highest log2 fold change was 8.2 for an unannotated lncRNA and 7.0 for NKAIN4, 
the highest upregulated annotated lncRNA. Among the downregulated lncRNAs, the highest log2 
fold change was 7.1 for an unannotated lncRNA gene and 6.9 for SSTR5, the highest 
downregulated annotated lncRNA. 
There was overlap in 206 lncRNAs as they were downregulated in ACC compared to 
NAC and ACC compared to ACA, and 355 lncRNAs overlapped as they were upregulated in 
ACC compared to NAC and ACA (Fig. 3).  
 
Differentially expressed lncRNAs in ACA versus NAC 
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 9 
Unsupervised hierarchical and heat map clustering showed that NAC samples clustered 
together with ACA samples (Fig. 1). Only ten lncRNAs were differentially expressed in ACA 
compared with NAC.  
 
Functional pathway analysis 
KEGG pathway analysis of the differentially expressed and annotated lncRNAs in ACC 
compared with NAC and ACC compared with ACA was performed to understand the biological 
relevance of these lncRNAs. Twenty-one pathways were significantly enriched in ACC versus 
ACA and 29 pathways were significantly enriched in ACC versus NAC (Tables 3 and 4). Twelve 
of the altered 21 pathways were common to the comparison of ACC versus ACA and ACC 
versus NAC. The KEGG pathways common to both comparisons included ‘Transcriptional 
misregulation in cancer’ and ‘ECM-receptor interaction’. 
 
Prognostic lncRNAs in ACC 
Using the survival data of the ACC TCGA cohort, the prognostic significance of 
HOTTIP, HOXA11-AS1, CRNDE, LINC00271, FAM211A-AS1 and TBXAS1 was analyzed. Only 
LINC00271 expression (Fig. 4A) was found to be associated with prognosis. LINC00271 
expression levels was positively associated with survival time (Fig. 4B). Median survival time for 
the low-LINC00271 expression group (n = 40) was 4.9 years, whereas it was not reached for the 
high-LINC00271 expression group (n = 39) (P < 0.019) (Fig 4C). Student’s t-tests demonstrated 
that LINC00271 expression levels of stage I tumors were significantly higher than those of stage 
IV tumors (P < 0.006). 
 
Identification of LINC00271-associated biological pathways by Gene Set Enrichment Analysis 
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To identify LINC00271-associated biological pathways, GSEA was performed using high 
throughput RNA-sequencing data from the TCGA ACC cohort. Among the GO gene sets, WNT 
signaling pathway, cell cycle, chromosome segregation and tissue morphogenesis were found to 
be significantly associated with low LINC00271 expression in the ACC TCGA cohort (Fig. 5), 
suggesting that LINC00271 may be involved in ACC development and/or progression through 
the above cancer-associated signaling pathways. 
 
LINC00271 copy number alterations  
An analysis of the LINC00271 chromosomal locus, 6q23.3, using genome-wide CGH 
array data that were previously generated in a cohort of NAC, ACA, and ACC
10
, was performed 
to examine whether the LINC00271 site demonstrated any copy number alterations to explain its 
downregulated expression in ACC. One out of 11 NAC samples demonstrated a deletion at 
6q23.3, whereas 2 of 18 ACA samples demonstrated deletions at 6q23.3 and two other ACA 
samples demonstrated amplifications at 6q23.3. The LINC00271 locus was most unstable in 
ACCs, with 4 of 19 ACC samples demonstrating deletions and 4 of 19 ACC samples 
demonstrating amplifications of 6q23.3. 
 
Discussion 
This study demonstrated that NAC, ACA and ACC have distinct lncRNA expression 
profiles, and that LINC00271, involved in biological pathways commonly dysregulated in ACC, 
is a prognostic marker in ACC.  
Eight hundred and seventy-four lncRNAs were differentially expressed in ACC compared 
with NAC, 1076 lncRNAs were differentially expressed in ACA compared with ACC, and only 
ten lncRNAs were differentially expressed in ACA vs. NAC. Previously, Glover and colleagues 
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demonstrated that the highest number of differentially expressed lncRNAs in their study were 
between ACA and NAC (2655 lncRNAs), while 956 lncRNAs were differentially expressed 
between ACC and NAC, and 85 lncRNAs were differentially expressed between ACC and 
ACA.
11
 They suggested that changes in lncRNA expression could be an early part in the 
pathogenesis of both ACC and ACAs. However, our results are not entirely consistent with their 
findings as we found only ten lncRNAs that were differentially expressed between ACA and 
NAC. However, this finding is in line with the multistep hypothesis in tumorigenesis that is 
present in most human cancers - progressive genetic/genomic alterations increasing/accumulating 
from NAC to ACA to ACC as previously described in our integrated genome-wide gene 
expression, gene methylation, microRNA expression and CGH analysis in human NAC, ACA 
and ACC samples.
8
 The multistep progression from NAC to ACA to ACC is further supported by 
our finding of 296 lncRNAs differentially expressed between ACA versus ACC and 465 
lncRNAs differentially expressed between ACC vs. NAC. Overall, we found less differently 
expressed lncRNAs in adrenocortical tumors compared to the Glover et al. study
11
 but we used a 
more stringent fold change cut-off to identify differentially expressed lncRNAs and the NAC 
samples used in our study were not adjacent normal tissue to ACAs. 
In the current study, the TCGA ACC dataset was used to screen for prognostic 
significance of differentially expressed lncRNAs. LINC00271 was found to be associated with 
malignancy, with patients with low LINC00271 expression levels surviving a significantly shorter 
time than patients with high LINC00271 expression levels. Previously, significantly lower 
expression of LINC00271 has been described in invasive breast carcinoma, lung adenocarcinoma, 
kidney renal papillary cell carcinoma, head and neck squamous cell carcinoma and papillary 
thyroid cancer.
17
 In addition, LINC00271 has been found to be an independent risk factor for 
extrathyroidal extension, lymph node metastasis, advanced tumor stage III/IV and recurrence in 
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papillary thyroid cancer.
17
 GSEA revealed that genes associated with cell adhesion molecules, 
TP53 signaling pathway, JAK/STAT signaling pathway and cell cycle were significantly 
enriched in papillary thyroid cancer with a low LINC00271 expression versus papillary thyroid 
cancer with higher LINC00271 expression. We also found that genes associated with cell cycle 
were associated with low LINC00271 expression in the TCGA ACC cohort. Further LINC00271 
expression was positively associated with WNT signaling pathway and chromosome segregation, 
biological pathways commonly dysregulated in ACC.
18,19
 Thus, our findings and other 
investigators studies suggest that LINC00271 could contribute to abnormal activation of these 
pathways in a tumor suppressor manner, however further mechanistic studies are needed to test 
this hypothesis.  
Studies have suggested that genes with causal roles in tumorigenesis are often located in 
chromosomal areas with copy number alterations.
20,21
 Gene expression levels are directly 
dependent on chromosomal aneuploidies in carcinomas.
22
 The strongest correlations have been 
found between genomic copy number and average chromosome-wide expression levels, but the 
expression of individual genes has also been associated with genomic copy numbers.
23
 LncRNAs 
expression levels have been positively correlated with copy number alterations as well.
24,25
 
Therefore, we investigated whether copy number alterations were present at the LINC00271 
chromosomal locus, 6q23.3. This region had the highest alteration in ACC samples with 21% of 
samples demonstrating amplifications and another 21% demonstrating deletions, while only 11% 
of ACA samples had amplifications and another 11% deletions of 6q23.3. The instability of 
6q23.3 might explain the dysregulated expression of LINC00271 in ACC. 
In conclusion, ACC has a distinct lncRNA expression profile, and LINC00271 
downregulation is associated with malignancy and is involved in biological pathways commonly 
dysregulated in ACC. 
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Tables 
 
Table 1. Clinical features of ACA and ACC patients 
 
 ACA* ACC† included in 
microarray 
ACC in validation 
cohort 
Number of patients 11 9 10 
Age (average ± SD) 46.0 years ± 18.7 52.2 years ± 14.7 46.7 years ± 13.7 
Sex (female/male) 9/2 7/2 6/4
 
Tumor size (average ± SD) 3.8 cm ± 1.8 6.7 cm ± 5.9 5.4 cm ± 2.2 
Functional 55% 44% 30% 
Syndrome‡      
  Adrenal     
  hypercortisolism 
3 4 3 
  Primary     
  hyperaldosteronism 
3 1 0 
  Nonfunctioning 6 4 7 
* ACA, adrenocortical adenoma 
† ACC, adrenocortical carcinoma 
‡ Functional status at initial presentation 
 
 
Table 2. Selected carcinogenesis-related differentially expressed lncRNAs between ACC and NAC 
 
Sequence name Gene symbol Regulation P-value Log2 fold 
change 
Chromosome Relationship 
ENST00000534886 
 
SRRM4  Up 0.001 5.14 Chr12 Intron sense-
overlapping 
ENST00000472494 
 
HOTTIP  Up 9.11 x 10-5 5.05 Chr7 Bidirectional 
ENST00000514846 
 
GRK6  Up 9.92 x 10-6 4.75 Chr5 Natural antisense 
NR_002795 
 
HOXA11  Up 4.61 x 10-5 4.05 Chr7 Bidirectional 
NR_045572 
 
CHL1  Up 3.45 x 10-4 4.16 Chr3 Exon sense-
overlapping 
       
ENST00000558031 
 
CRNDE Up 1.30 x 10-5 2.45 Chr16 Intergenic 
ENST00000502941 
 
HAND2  Down 1.52 x 10-7 6.35 Chr4 Bidirectional 
ENST00000450445 
 
BNC2  Down 1.36 x 10-6 5.01 Chr9 Intronic antisense 
ENST00000417354 
 
DNM3  Down 4.46 x 10-6 3.50 Chr1 Intronic antisense 
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NR_029394 
 
TBXAS1  Down 2.15 x 10-4 2.51 Chr7 Exon sense-
overlapping 
NR_026805 
 
LINC00271  Down 3.99 x 10-6 2.50 Chr6 Bidirectional 
NR_027158.1 FAM211A-AS1  Down 2.96 x 10-3 2.06 Chr17 Intronic antisense 
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Table 3. Significantly different KEGG pathways in ACC versus ACA 
 
Pathways Genes P-value 
Pathways in cancer 
ADCY2, RALBP1, CSF2RA, DAPK1, FGF13, GSK3B, BIRC5, 
ITGA3, MMP9, PTGER3, SLC2A1, TGFB2, PAX8, RUNX1 1.791e-3 
Vascular smooth muscle contraction KCNMB2, ADCY2, KCNMA1, AVPR1A, PRKCQ, PRKG1 3.251e-3 
Glucagon signaling pathway ADCY2, PRKAG2, PGAM2, PHKA2, SLC2A1 5.823e-3 
Malaria ITGAL, TGFB2, THBS4 7.960e-3 
Transcriptional misregulation in cancer 
HOXA10, HOXA11, MMP9, PAX8, HMGA2, HIST1H3G, 
RUNX1 8.716e-3 
Insulin secretion KCNMB2, ADCY2, KCNMA1, SLC2A1 1.209e-2 
Circadian rhythm ADCY2, PRKG1, PTGER3 1.266 e-2 
Salivary secretion NPAS2, PRKAG2 1.346 e-2 
Cell cycle ADCY2, KCNMA1, LYZ, PRKG1 1.455 e-2 
Colorectal cancer E2F5, GSK3B, MAD2L1, RBL2, TGFB2 1.522 e-2 
FoxO signaling pathway GSK3B, BIRC5, TGFB2 1.786 e-2 
Glycolysis / Gluconeogenesis S1PR1, PRKAG2, RBL2, BNIP3, TGFB2 2.149 e-2 
Ubiquitin mediated proteolysis PGAM2, ADPGK, FBP2 2.307 e-2 
Adipocytokine signaling pathway UBE2S, UBE2D4, SIAH1, UBE2G2, ITCH 2.367 e-2 
Signaling pathways regulating pluripotency of stem 
cells PRKAG2, PRKCQ, SLC2A1 2.661 e-2 
Bladder cancer ESRRB, GSK3B, PAX6, POU5F1B, PCGF1 2.762 e-2 
Insulin resistance DAPK1, MMP9 2.841 e-2 
RNA degradation GSK3B, PRKAG2, PRKCQ, SLC2A1 3.180 e-2 
ECM-receptor interaction LSM1, EXOSC10, BTG1 3.605 e-2 
Hypertrophic cardiomyopathy (HCM) SV2C, ITGA3, THBS4 4.385e-2 
Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type 
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Table 4. Significantly different KEGG pathways in ACC versus NAC  
 
Pathways Genes P-value 
ECM-receptor interaction COL6A2, SV2C, ITGA3, ITGA9, THBS2 5.329e-4 
Circadian rhythm NPAS2, PRKAG2, BHLHE40 5.596e-4 
Vascular smooth muscle contraction 
MRVI1, KCNMA1, AVPR1A, PRKACB, PRKCQ, 
PRKG1 7.222e-4 
Adipocytokine signaling pathway IKBKB, PRKAG2, PRKCQ, SLC2A1 1.759e-3 
Transcriptional misregulation in cancer 
HOXA11, MEIS1, MMP9, UTY, PAX8, HMGA2, 
HIST1H3G 1.785e-3 
Cocaine addiction GRIN3B, GRM3, PRKACB 3.175e-3 
Salivary secretion KCNMA1, LYZ, PRKACB, PRKG1 5.0121e-3 
Glucagon signaling pathway PRKAG2, PGAM2, PRKACB, SLC2A1 8.511e-3 
Glycolysis / Gluconeogenesis ADH1A, PGAM2, ADPGK 9.687e-3 
Insulin resistance IKBKB, PRKAG2, PRKCQ, SLC2A1 1.161e-2 
Nicotine addiction CHRNA4, GRIN3B 1.345e-2 
Proteasome PSMA3, PSMD7 1.740e-2 
Platelet activation LYN, PRKACB, PRKG1, TBXAS1 1.817e-2 
Hypertrophic cardiomyopathy (HCM) ITGA3, ITGA9, PRKAG2 1.998e-2 
Hedgehog signaling pathway CDON, PRKACB 2.074e-2 
Endocrine and other factor-regulated calcium reabsorption DNM3, PRKACB 2.074e-2 
Insulin secretion KCNMA1, PRKACB, SLC2A1 2.161e-2 
Neuroactive ligand-receptor interaction 
CHRNA4, GRIN3B, GRM3, AVPR1A, RXFP1, SSTR5, 
THRB 2.227e-2 
Dilated cardiomyopathy ITGA3, ITGA9, PRKACB 2.602e-2 
Morphine addiction GRK6, PDE4D, PRKACB 2.697e-2 
NF-kappa B signaling pathway IKBKB, LYN, PRKCQ 2.891e-2 
Circadian entrainment PRKACB, PRKG1, CACNA1H 3.094e-2 
Regulation of lipolysis in adipocytes PRKACB, PRKG1 3.273e-2 
Long-term depression LYN, PRKG1 3.900e-2 
Focal adhesion COL6A2, ITGA3, ITGA9, PAK3, THBS2 4.064e-2 
T cell receptor signaling pathway IKBKB, PAK3, PRKCQ 4.110e-2 
Longevity regulating pathway – multiple species PRKAG2, PRKACB 4.584e-2 
Renin secretion KCNMA1, PRKACB 4.584e-2 
Renal cell carcinoma PAK3, SLC2A1 4.946e-2 
Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type 
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Figure legends 
 
Fig 1. Unsupervised hierarchical clustering and heat map of lncRNA expression between 
adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA) and normal adrenal cortex 
(NAC). Each column represents a sample and each row represents a lncRNA. High relative 
expression is indicated in yellow and low relative expression in red. 
 
Fig 2. TaqMan qRT-PCR validation of lncRNA microarray analysis. Fold change in comparison 
of adrenocortical carcinoma versus normal adrenal cortex, *P < 0.05.  
 
Fig 3. Venn diagram showing the number of overlapping up- or downregulated lncRNAs in the 
different comparisons. ACC, adrenocortical carcinoma; ACA, adrenocortical adenoma; NAC, 
normal adrenal cortex.  
 
Fig 4. LINC00271 expression and prognosis. A, Distribution of LINC00271 expression of 
adrenocortical carcinoma samples from the TCGA dataset. Red points were defined as low-
LINC00271 expression group and black points were defined as high-LINC00271 expression 
group. B, LINC00271 expression is positively correlated to survival time (Pearson correlation 
coefficient = 0.50). C, Kaplan-Meier plot of overall survival in the TCGA adrenocortical 
carcinoma cohort is shown according to LINC00271 expression level (low vs. high).  
 
Fig 5. LINC00271-associated biological signaling pathways. Based on the TCGA dataset, GSEA 
showed that genes associated with WNT signaling pathway, cell cycle, chromosome segregation 
and tissue morphogenesis were significantly enriched in lower LINC00271 versus higher 
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LINC00271 expressing adrenocortical carcinomas. FDR, false discovery rate; NES, normalized 
enrichment score. 
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Abstract 
Background: Adrenocortical carcinoma (ACC) is an aggressive malignancy with a low but 
variable overall survival rate. The role of long, noncoding RNAs (lncRNAs) in ACC is poorly 
understood. Thus, in this study we performed lncRNA expression profiling in ACCs, 
adrenocortical adenomas (ACA), and normal adrenal cortex (NAC). 
Methods: LncRNA expression profile, using ArrayStar Human LncRNA/mRNA Expression 
Microarray V3.0, was analyzed in samples from 11 ACA, 9 ACC, and 5 NAC samples. 
Differentially expressed lncRNAs were validated using TaqMan, real-time quantitative PCR with 
additional samples. The dataset from the ACC Cancer Genome Atlas (TCGA) project dataset was 
used to evaluate the prognostic utility of lncRNAs.  
Results: Unsupervised hierarchical clustering showed distinct clustering of ACC samples 
compared with NAC and ACA samples by lncRNA expression profiles. A total of 874 lncRNAs 
were differentially expressed between ACC and NAC. LINC00271 expression level was 
associated with  prognosis, patients with low LINC00271 expression survived a a significantly 
shorter time time than patients with high LINC00271 expression. Low LINC00271 expression 
was positively associated with WNT signaling, cell cycle, and chromosome segregation 
pathways.  
Conclusions: ACC has a distinct lncRNA expression profile. LINC00271 is downregulated in 
ACC and appears to be is involved in biological pathways commonly dysregulated in ACC. 
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Introduction 
 Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with an annual 
incidence of 0.7–2.0 cases per million people and a five-year overall survival rate ranging from 
32% to 47%).
1,2
 Furthermore, even after complete tumor resection, over half of the patients 
develop recurrent disease.
3
 Patients with locally advanced and metastatic ACC often undergo 
therapy with , which consists of a regimen, including adrenolytic mitotane plus combination 
chemotherapy with etoposide, doxorubicin, and cisplatin. Unfortunately, this regimen has very 
limited therapeutic benefit.
4
 The role of adjuvant therapy for ACC is controversial because of 
questionable therapeutic benefit of current agents and the heterogenous prognosis.
3
 
Understanding the mechanism behind the  ACC initiation and progression of ACC could help in 
identifying diagnostic and prognostic markers, and therapeutic targets.  
Several genomic studies of ACC have reported aon distinct, ACC genome-wide gene 
expression and alteration profiles of, micro-RNA expression, methylation, and copy number 
alteration profiles compared with adrenal cortical adenomas (ACAs) and normal adrenal cortex 
(NAC).
5-10
 These studies have led to the molecular classification of ACC that is relevant for 
predicting prognosis. Recently, long, noncoding RNAs (lncRNAs) have been suggested to be 
dysregulated in ACC.
11
 LncRNAs are RNA transcripts longer than 200 nucleotides that do not 
encode protein and are localized in the cell nucleus or cytoplasm.
12
 The expression of lncRNAs is 
more tissue- specific than protein-coding genes, and they function as decoys, scaffolds, and 
enhancer RNAs and are involved in chromatin remodeling, as well as transcriptional and post-
transcriptional regulation.
13 
To our knowledge, the study by Glover and colleagues has been the only study that has 
investigated lncRNA expression profile in ACCs, ACAs, and NAC.
11
 These investigatorsy 
reported that the greathighest number of differentially expressed lncRNAs were between ACAs 
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 6 
and NAC, with almost 3-fold less lncRNAs being differentially expressed between ACCs and 
NAC. This finding suggested that changes in lncRNA expression could be an early event in the 
pathogenesis of both ACC and ACAs. However, tThis finding, however, is in contrast to the 
results of previous, genome-wide analysesis results that demonstrated a multistep progression in 
ACC, with increasing genomic changes from NAC to ACA to ACC.
8
 Therefore, to further our 
knowledge of the role of lncRNA in ACCs, we performed lncRNA expression profiling using 
lncRNA microarrays to identify differentially expressed lncRNAs in ACCs compared with NACs 
and ACAs. We also investigated whether lncRNA expression levels were associated with ACC 
overall survival times.  of ACCs.   
 
Materials and methods 
Tissue samples 
Patients’ tumor tissues were procured after informed consent for genetic studies on a 
procurement clinical protocol pproved by our n Institutional Review Board-approved 
procurement clinical protocol (NCT01005654 and NCT01348698). The tissues were immediately 
snap frozen in liquid nitrogen and stored at -80°C. For this study, we used 11 ACA samples and 
nine ACC samples. Five normal NACs were obtained at the time of organ donation harvesting. 
These 25 tissue samples were used for lncRNA microarray profiling. In addition to these 
samples, an additional 10 ACC samples were included in the quantitative RT-PCR (qRT-PCR) 
validation (Table 1). Tumors were classified as benign when the Weiss criteria scores were less 
than 3 (all the benign samples included had a Weiss score of 0), and tumors were classified as 
ACC, when the Weiss criteria scores were more than or equal to 3.
14
 Only samples with at least 
80% tumor cells were included for analysis. 
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RNA extraction  
Total RNA was extracted from fresh frozen tissue samples using an RNeasy Mini Kit 
(Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. RNA quality was 
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Englewood, CO, USA). 
Only samples with a minimum RNA integrity number of seven were included for analysis. 
 
Microarray profiling  
The ArrayStar Human LncRNA/mRNA Expression Microarray Version 3.0 (ArrayStar, 
Inc., Rockville, MD, USA) was used for lncRNA profiling, which includes 30,586 lncRNA 
probes and 26,109 coding transcripts, for lncRNA profiling. RNA labeling, microarray 
hybridization, slide washing, and scanning were performed based on the standard protocols of the 
ArrayStar. Agilent Feature Extraction software (version 11.0.1.1) which was used to analyze 
acquired array images. The microarray specifications and derived data are accessible through 
National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) 
accession number GSE124531. 
 
TaqMan real-time quantitative PCR 
RNA was reverse transcribed using the High Capacity, cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA, USA). TaqMan qRT-PCR was performed using the 
7900HT, fast, real-time PCR systems (Applied Biosystems). The reaction contained cDNA, 
TaqMan 2×universal PCR master mix, and TaqMan gene expression assays primers (Applied 
Biosystems). LncRNAs were selected for validation based on three criteria: 1) availability of 
validated TaqMan gene expression primer/probe assays, 2) possible role in cancer, and 3) 
magnitude of differential expression. The gene expression assays used were: HOTTIP 
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 8 
(Hs03649396_m1), CHL1 (Hs04332026_m1), HOXA11-AS1 (Hs_03454334_g1), CRNDE 
(HS04404483_m1), LINC00271 (Hs03657384_m1), FAM211A-AS1 (Hs03678558_g1), TBXAS1 
(Hs01096058_s1) and GAPDH (Hs99999905_m1). 
 
Comparative genomic hybridization (CGH) array analysis 
We used our previously published, genome-wide, CGH array data in a cohort of NAC, 
ACA, and ACC.
8
 The LINC100271 site was scanned manually scanned for its copy number 
status using Nexus software.  
 
Statistical and data analysis 
LncRNA expression profiles of ACC samples were compared with NAC and ACA 
samples. The Gaussian linear model was used to calculate P-values, and false discovery rates 
(FDRs) were calculated using the Benjamini-Hochberg method for each lncRNA. LncRNAs with 
a log2 fold change ≥2 and an FDR <0.05 were defined as differentially expressed lncRNAs. 
Differentially expressed lncRNAs were mapped to their associated gene names, and then a gene 
set enrichment analysis (GSEA) was performed on these genes. An in-house. R package, 
OmicPath (v 0.1) was used to perform the GSEA to discover potential KEGG pathway 
associations for each set of differentially expressed lncRNAs. Pathways with a P-value < 0.05 
were considered statistically significant. Survival curves were plotted using the Kaplan-Meier 
methods, and differences in survival rates were determined using the log-rank test. These 
statistical analyses were done with GraphPad Software with and P < 0.05 was considered 
statistically significant.  
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 9 
The ACC cohort from the project database of the Cancer Genome Atlas (TCGA) project 
database (https://tcga-data.nci.nih.gov/tcga/) which included 79 patients with HOTTIP, CHL1, 
HOXA11-AS1, CRNDE, LINC00271, FAM211A-AS1 and TBXAS1 expression data, as well as 
follow-up information, were used to study the prognostic importancesignificance  of lncRNAs. 
For the  overall survival analysis, two groups were defined based on the lncRNA expression 
levels in the primary tumor. Those with a lncRNA level ranked in the top half were classified into 
the high expression group and the rest into the low expression group based on the median value.  
 The gene expression profiles of ACC samples deposited in the TCGA project database 
were analyzed to compare expression patterns in tumors with high (n = 39) vs. low LINC100271 
expression (n = 40). The downloaded data consisted of quantified gene expression data, that were 
further processed using the DESeq2 package.
15
 The differentialy expressed genes were annotated, 
and GSEA analysis was performed using the clusterProfiler package.
16
  
 
Results 
Differentially expressed lncRNAs in ACC versus NAC 
Unsupervised hierarchical and heat map clustering showed distinct clustering of ACC 
samples compared with NAC and ACA samples (Fig. 1). In these samples, 874 Eight hundred 
and seventy-four lncRNAs were differentially expressed in ACC compared with NAC, of which 
409 were upregulated, and 465 were downregulated. The 874 differentially expressed lncRNAs 
corresponded to 330 annotated lncRNA genes. Among the upregulated lncRNAs, the greathighest 
log2 fold change was 8.5 for an unannotated lncRNA gene, and RAD50 was the gerathighest 
upregulated, annotated lncRNA gene with a log2 fold change of 6.1. Among the downregulated 
lncRNAs, the greathighest log2 fold change was 8.3 for an unannotated lncRNA gene and 6.4 for 
HAND2, the greathighest downregulated annotated lncRNA gene; of these, 183. One hundred and 
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 10 
eighty-three differently expressed lncRNAs had established functions in cancer development and 
cancer progression. Selected carcinogenesis-related lncRNAs are summarized in Table 2.  
To test the validity of the microarray findings, seven lncRNAs (HOTTIP, CHL1, 
HOXA11-AS1, CRNDE, LINC00271, FAM211A-AS1 and TBXAS1) were selected among the 
carcinogenesis-related, differentially expressed lncRNAs, and their expression was analyzed by 
TaqMan qRT-PCR. The validation cohort included 19 ACC samples and 5 NAC samples. 
HOTTIP, HOXA11-AS1 and CRNDE were overexpressed in ACC (P  < 0.05) and confirmed by 
TaqMan qRT-PCR in the validation cohort (P < 0.05; Fig. 2). Expression of LINC00271, 
FAM211A-AS1 and TBXAS1 expression was downregulated in ACC (P < 0.05) and also by 
TaqMan qRT-PCR (P < 0.05) (Fig 2). The microarray result for CHL1 was not confirmed in the 
validation cohort. Upregulated expression of CHL1 was identified in the microarray analysis (P < 
0.05) while CHL1 was found not to be not significantly upregulated by TaqMan qRT-PCR in the 
validation cohort.  
 
Differentially expressed lncRNAs in ACC versus ACA 
When comparing ACC with ACA, 1076 One thousand seventy-six lncRNAs were 
differentially expressed in ACC compared with ACA, of which 780 were upregulated, and 296 
were downregulated. The 1,076, differentially expressed lncRNAs corresponded to 376 annotated 
lncRNA genes. Among the upregulated lncRNAs, the greathighest log2 fold change was 8.2 for 
an unannotated lncRNA and 7.0 for NKAIN4, the greathighest upregulated annotated lncRNA. 
Among the downregulated lncRNAs, the greathighest log2 fold change was 7.1 for an 
unannotated lncRNA gene and 6.9 for SSTR5, the greathighest downregulated annotated lncRNA. 
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There was overlap in 206 lncRNAs as they were downregulated in ACC compared to 
NAC and in ACC compared to ACA, and 355 lncRNAs overlapped as they were upregulated in 
ACC compared to NAC and ACA (Fig. 3).  
 
Differentially expressed lncRNAs in ACA versus NAC 
Unsupervised hierarchical and heat map clustering showed that NAC samples clustered 
together with ACA samples (Fig. 1). Only10 ten lncRNAs were differentially expressed in ACA 
compared with NAC.  
 
Functional pathway analysis 
KEGG pathway analysis of the differentially expressed and annotated lncRNAs in ACC 
compared with NAC and in ACC compared with ACA was performed to understand the 
biological relevance of these lncRNAs. Twenty-one pathways were significantly enriched in 
ACC versus ACA and 29 pathways were significantly enriched in ACC versus NAC (Tables 3 
and 4). Twelve of the altered 21 pathways were common to the comparison of ACC versus ACA 
and ACC versus NAC. The KEGG pathways common to both comparisons included 
‘Transcriptional misregulation in cancer’ and ‘ECM-receptor interaction’. 
 
Prognostic lncRNAs in ACC 
Using the survival data of the ACC TCGA cohort, the prognostic significance of 
HOTTIP, HOXA11-AS1, CRNDE, LINC00271, FAM211A-AS1 and TBXAS1 was analyzed. Only 
LINC00271 expression (Fig. 4A) was found to be associated with prognosis. LINC00271 
expression levels wereas positively associated with survival time (Fig. 4B). Median survival time 
for the low-LINC00271 expression group (n = 40) was 4.9 years, whereas it was not reached for 
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the high-LINC00271 expression group (n = 39) (P < 0.019) (Fig 4C). Student’s t-tests 
demonstrated that LINC00271 expression levels of stage I tumors were greatsignificantly higher 
than those of stage IV tumors (P < 0.006). 
 
Identification of LINC00271-associated biological pathways by Gene Set Enrichment Analysis 
To identify LINC00271-associated biological pathways, GSEA was performed using high 
throughput, RNA-sequencing data from the TCGA ACC cohort. Among the GO gene sets, the 
WNT signaling pathway, cell cycle, chromosome segregation, and tissue morphogenesis were 
found to be sitatisticallygnificantly associated with low LINC00271 expression in the ACC 
TCGA cohort (Fig. 5), suggesting that LINC00271 may be involved in ACC development and/or 
progression through the above cancer-associated signaling pathways. 
 
LINC00271 copy number alterations  
We performed aAn analysis of the LINC00271 chromosomal locus, 6q23.3, using 
genome-wide. CGH array data that were previously generated previously in a cohort of NAC, 
ACA, and ACC
10
, was performed to examine whether the LINC00271 site demonstrated any 
copy number alterations to explain its downregulated expression in ACC. One out of 11 NAC 
samples demonstrated a deletion at 6q23.3, whereas 2 of 18 ACA samples demonstrated deletions 
at 6q23.3, and two other ACA samples demonstrated amplifications at 6q23.3. The LINC00271 
locus appeared to be the was most unstable in ACCs, with 4 of 19 ACC samples demonstrating 
deletions, and 4 of 19 ACC samples demonstrating amplifications of 6q23.3. 
 
Discussion 
This study demonstrated that NAC, ACA, and ACC have distinct lncRNA expression 
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profiles, and that LINC00271, 2whhich aappeared to be involved in biological pathways 
commonly dysregulated in ACC, may beis a prognostic marker in ACC.  
When compared with NAC, 874 Eight hundred and seventy-four lncRNAs were 
differentially expressed in ACC, compared with NAC, 1076 lncRNAs were differentially 
expressed in ACA compared with ACC, and only t10en lncRNAs were differentially expressed in 
ACA vs. NAC. Previously, Glover and colleagues demonstrated that the greathighest number of 
differentially expressed lncRNAs in their study wasere between ACA and NAC (2655 lncRNAs), 
while 956 lncRNAs were differentially expressed between ACC and NAC, and 85 lncRNAs were 
differentially expressed between ACC and ACA.
11
 The data of these investiagotrs y suggested 
that changes in lncRNA expression could be an early part in the pathogenesis of both ACC and 
ACAs. In contrast, However, our results are not entirely consistent with their findings, because as 
we found only 10ten lncRNAs that were differentially expressed between ACA and NAC.; 
However, this finding is in line with the multistep hypothesis in tumorigenesis that is present in 
most human cancers - progressive genetic/genomic alterations increasing/accumulating from 
NAC to ACA to ACC as previously described previously in our integrated, genome-wide gene 
expression, gene methylation, microRNA expression, and CGH analysis in human samples form 
NACs, ACAs, and ACCs samples.
8
 The multistep progression from NAC to ACA to ACC is 
further supported by our finding of 296 lncRNAs differentially expressed between ACA versus 
ACC and 465 lncRNAs differentially expressed between ACC vs. NAC. Overall, we found less 
differently expressed lncRNAs in adrenocortical neoplasmstumors compared to the Glover et al. 
study
11,
 but we used a more stringent cut-off in fold- change cut-off to identify differentially 
expressed lncRNAs, and the NAC samples used in our study were not adjacent normal tissue to 
ACAs. 
In the current study, the TCGA ACC dataset was used to screen for prognostic 
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significance of differentially expressed lncRNAs. LINC00271 was found to be associated with 
malignancy;, with patients with low LINC00271 expression levels surviveding a significantly 
lessershorter time than patients with high LINC00271 expression levels. Previously, a 
statidtifvally significantly lessower expression of LINC00271 has been described in invasive 
breast carcinoma, lung adenocarcinoma, kidney renal papillary cell carcinoma, head and neck 
squamous cell carcinoma, and papillary thyroid cancer.
17
 In addition, LINC00271 has been found 
to be an independent risk factor for extrathyroidal extension, lymph node metastasis, advanced 
tumor stage III/IV, and recurrence in papillary thyroid cancer.
17
 GSEA revealed that genes 
associated with cell adhesion molecules, the TP53 signaling pathway, the JAK/STAT signaling 
pathway, and the cell cycle were statistically ignificantly enriched in papillary thyroid cancer 
with a low LINC00271 expression versus papillary thyroid cancer with greathigher LINC00271 
expression. We also found that genes associated with cell cycle were associated with low 
LINC00271 expression in the TCGA ACC cohort. Further LINC00271 expression was positively 
associated with gthe WNT signaling pathway and chromosome segregation which are, biological 
pathways commonly dysregulated in ACC.
18,19
 Thus, our findings and other investigators studies 
suggest that LINC00271 could contribute to abnormal activation of these pathways in a tumor 
suppressor manner, however, further mechanistic studies are needed to test this hypothesis.  
Studies have suggested that genes with causal roles in tumorigenesis are often located in 
chromosomal areas with alterations in copy number alterations.
20,21
 Gene expression levels are 
directly dependent on chromosomal aneuploidies in carcinomas.
22
 The strongest correlations have 
been found between genomic copy number and average, chromosome-wide expression levels, but 
the expression of individual genes has also been associated with genomic copy numbers.
23
 
LncRNAs expression levels have been positively correlated with alterations in copy number 
alterations as well.
24,25
 Therefore, we investigated whether alterations in copy number alterations 
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were present at the LINC00271 chromosomal locus, 6q23.3. This region had the greathighest 
alteration in ACC samples with 21% of samples demonstrating amplifications and another 21% 
demonstrating deletions, while only 11% of ACA samples had amplifications and another 11% 
deletions of 6q23.3. The instability of 6q23.3 might explain the dysregulated expression of 
LINC00271 in ACC. 
In conclusion, ACC has a distinct lncRNA expression profile, and LINC00271 
downregulation is appears to be associated with malignancy and may beis involved in biological 
pathways commonly dysregulated in ACC. 
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Tables 
 
Table 1. Clinical features of ACA and ACC patients 
 
 ACA* ACC† included in 
microarray 
ACC in validation 
cohort 
Number of patients 11 9 10 
Age (average ± SD) 46.0 years ± 198.7 52.2 years ± 154.7 46.7 years ± 143.7 
Sex (female/male) 9/2 7/2 6/4
 
Tumor size (average ± SD) 3.8 cm ± 1.8 6.7 cm ± 5.9 5.4 cm ± 2.2 
Functional 55% 44% 30% 
Syndrome‡      
  Adrenal     
  hypercortisolism 
3 4 3 
  Primary     
  hyperaldosteronism 
3 1 0 
  Nonfunctioning 6 4 7 
* ACA, adrenocortical adenoma 
† ACC, adrenocortical carcinoma 
‡ Functional status at initial presentation 
 
 
Table 2. Selected carcinogenesis-related differentially expressed lncRNAs between ACC and NAC 
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Sequence name Gene symbol Regulation P-value Log2 fold 
change 
Chromosome Relationship 
ENST00000534886 
 
SRRM4  Up 0.001 5.14 Chr12 Intron sense-
overlapping 
ENST00000472494 
 
HOTTIP  Up 9.11 x 10-5 5.05 Chr7 Bidirectional 
ENST00000514846 
 
GRK6  Up 9.92 x 10-6 4.75 Chr5 Natural antisense 
NR_002795 
 
HOXA11  Up 4.61 x 10-5 4.05 Chr7 Bidirectional 
NR_045572 
 
CHL1  Up 3.45 x 10-4 4.16 Chr3 Exon sense-
overlapping 
       
ENST00000558031 
 
CRNDE Up 1.30 x 10-5 2.45 Chr16 Intergenic 
ENST00000502941 
 
HAND2  Down 1.52 x 10-7 6.35 Chr4 Bidirectional 
ENST00000450445 
 
BNC2  Down 1.36 x 10-6 5.01 Chr9 Intronic antisense 
ENST00000417354 
 
DNM3  Down 4.46 x 10-6 3.50 Chr1 Intronic antisense 
NR_029394 
 
TBXAS1  Down 2.15 x 10-4 2.51 Chr7 Exon sense-
overlapping 
NR_026805 
 
LINC00271  Down 3.99 x 10-6 2.50 Chr6 Bidirectional 
NR_027158.1 FAM211A-AS1  Down 2.96 x 10-3 2.06 Chr17 Intronic antisense 
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Table 3. Statistically significantly different KEGG pathways in ACC versus ACA 
 
Pathways Genes P-value 
Pathways in cancer 
ADCY2, RALBP1, CSF2RA, DAPK1, FGF13, GSK3B, BIRC5, 
ITGA3, MMP9, PTGER3, SLC2A1, TGFB2, PAX8, RUNX1 1.791e-3 
Vascular smooth muscle contraction KCNMB2, ADCY2, KCNMA1, AVPR1A, PRKCQ, PRKG1 3.251e-3 
Glucagon signaling pathway ADCY2, PRKAG2, PGAM2, PHKA2, SLC2A1 5.823e-3 
Malaria ITGAL, TGFB2, THBS4 7.960e-3 
Transcriptional misregulation in cancer 
HOXA10, HOXA11, MMP9, PAX8, HMGA2, HIST1H3G, 
RUNX1 8.716e-3 
Insulin secretion KCNMB2, ADCY2, KCNMA1, SLC2A1 1.209e-2 
Circadian rhythm ADCY2, PRKG1, PTGER3 1.266 e-2 
Salivary secretion NPAS2, PRKAG2 1.346 e-2 
Cell cycle ADCY2, KCNMA1, LYZ, PRKG1 1.455 e-2 
Colorectal cancer E2F5, GSK3B, MAD2L1, RBL2, TGFB2 1.522 e-2 
FoxO signaling pathway GSK3B, BIRC5, TGFB2 1.786 e-2 
Glycolysis / Gluconeogenesis S1PR1, PRKAG2, RBL2, BNIP3, TGFB2 2.149 e-2 
Ubiquitin mediated proteolysis PGAM2, ADPGK, FBP2 2.307 e-2 
Adipocytokine signaling pathway UBE2S, UBE2D4, SIAH1, UBE2G2, ITCH 2.367 e-2 
Signaling pathways regulating pluripotency of stem 
cells PRKAG2, PRKCQ, SLC2A1 2.661 e-2 
Bladder cancer ESRRB, GSK3B, PAX6, POU5F1B, PCGF1 2.762 e-2 
Insulin resistance DAPK1, MMP9 2.841 e-2 
RNA degradation GSK3B, PRKAG2, PRKCQ, SLC2A1 3.180 e-2 
ECM-receptor interaction LSM1, EXOSC10, BTG1 3.605 e-2 
Hypertrophic cardiomyopathy (HCM) SV2C, ITGA3, THBS4 4.385e-2 
Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type 
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Table 4. Statistically significantly different KEGG pathways in ACC versus NAC  
 
Pathways Genes P-value 
ECM-receptor interaction COL6A2, SV2C, ITGA3, ITGA9, THBS2 5.329e-4 
Circadian rhythm NPAS2, PRKAG2, BHLHE40 5.596e-4 
Vascular smooth muscle contraction 
MRVI1, KCNMA1, AVPR1A, PRKACB, PRKCQ, 
PRKG1 7.222e-4 
Adipocytokine signaling pathway IKBKB, PRKAG2, PRKCQ, SLC2A1 1.759e-3 
Transcriptional misregulation in cancer 
HOXA11, MEIS1, MMP9, UTY, PAX8, HMGA2, 
HIST1H3G 1.785e-3 
Cocaine addiction GRIN3B, GRM3, PRKACB 3.175e-3 
Salivary secretion KCNMA1, LYZ, PRKACB, PRKG1 5.0121e-3 
Glucagon signaling pathway PRKAG2, PGAM2, PRKACB, SLC2A1 8.511e-3 
Glycolysis / Gluconeogenesis ADH1A, PGAM2, ADPGK 9.687e-3 
Insulin resistance IKBKB, PRKAG2, PRKCQ, SLC2A1 1.161e-2 
Nicotine addiction CHRNA4, GRIN3B 1.345e-2 
Proteasome PSMA3, PSMD7 1.740e-2 
Platelet activation LYN, PRKACB, PRKG1, TBXAS1 1.817e-2 
Hypertrophic cardiomyopathy (HCM) ITGA3, ITGA9, PRKAG2 1.998e-2 
Hedgehog signaling pathway CDON, PRKACB 2.074e-2 
Endocrine and other factor-regulated calcium reabsorption DNM3, PRKACB 2.074e-2 
Insulin secretion KCNMA1, PRKACB, SLC2A1 2.161e-2 
Neuroactive ligand-receptor interaction 
CHRNA4, GRIN3B, GRM3, AVPR1A, RXFP1, SSTR5, 
THRB 2.227e-2 
Dilated cardiomyopathy ITGA3, ITGA9, PRKACB 2.602e-2 
Morphine addiction GRK6, PDE4D, PRKACB 2.697e-2 
NF-kappa B signaling pathway IKBKB, LYN, PRKCQ 2.891e-2 
Circadian entrainment PRKACB, PRKG1, CACNA1H 3.094e-2 
Regulation of lipolysis in adipocytes PRKACB, PRKG1 3.273e-2 
Long-term depression LYN, PRKG1 3.900e-2 
Focal adhesion COL6A2, ITGA3, ITGA9, PAK3, THBS2 4.064e-2 
T cell receptor signaling pathway IKBKB, PAK3, PRKCQ 4.110e-2 
Longevity regulating pathway – multiple species PRKAG2, PRKACB 4.584e-2 
Renin secretion KCNMA1, PRKACB 4.584e-2 
Renal cell carcinoma PAK3, SLC2A1 4.946e-2 
Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type 
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Figure legends 
 
Fig 1. Unsupervised hierarchical clustering and heat map of lncRNA expression between 
adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA), and normal adrenal cortex 
(NAC). Each column represents a sample, and each row represents a lncRNA. High relative 
expression is indicated in yellow and low relative expression in red. 
 
Fig 2. TaqMan qRT-PCR validation of lncRNA microarray analysis. Fold- change in comparison 
of ACCadrenocortical carcinoma versus NACnormal adrenal cortex, *P < 0.05.  
 
Fig 3. Venn diagram showing the number of overlapping up- or downregulated lncRNAs in the 
different comparisons. ACC, adrenocortical carcinoma; ACA, adrenocortical adenoma; NAC, 
normal adrenal cortex.  
 
Fig 4. LINC00271 expression and prognosis. A, Distribution of LINC00271 expression of ACC 
adrenocortical carcinoma samples from the TCGA dataset. Red points were defined as low-
LINC00271 expression group and black points were defined as high-LINC00271 expression 
group. B, LINC00271 expression is positively correlated to survival time (Pearson correlation 
coefficient = 0.50). C, Kaplan-Meier plot of overall survival in the TCGA the ACCadrenocortical 
carcinoma cohort is shown according to LINC00271 expression level (low vs. high).  
 
Fig 5. LINC00271-associated biological signaling pathways. Based on the TCGA dataset, GSEA 
showed that genes associated with WNT signaling pathway, cell cycle, chromosome segregation 
and tissue morphogenesis were statistically ignificantly enriched in lower LINC00271 versus 
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greathigher LINC00271 expressing adrenocortical carcinomasACCs. FDR, false discovery rate; 
NES, normalized enrichment score. 
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Abstract 
Background: Adrenocortical carcinoma (ACC) is an aggressive malignancy with a low but 
variable overall survival rate. The role of long, noncoding RNAs (lncRNAs) in ACC is poorly 
understood. Thus, in this study we performed lncRNA expression profiling in ACCs, 
adrenocortical adenomas (ACA), and normal adrenal cortex (NAC). 
Methods: LncRNA expression profile using ArrayStar Human LncRNA/mRNA Expression 
Microarray V3.0 was analyzed in samples from 11 ACA, 9 ACC, and 5 NAC. Differentially 
expressed lncRNAs were validated using TaqMan, real-time quantitative PCR with additional 
samples. The dataset from the ACC Cancer Genome Atlas (TCGA) project was used to evaluate 
the prognostic utility of lncRNAs.  
Results: Unsupervised hierarchical clustering showed distinct clustering of ACC samples 
compared with NAC and ACA samples by lncRNA expression profiles. A total of 874 lncRNAs 
were differentially expressed between ACC and NAC. LINC00271 expression level was 
associated with  prognosis, patients with low LINC00271 expression survived a shorter time than 
patients with high LINC00271 expression. Low LINC00271 expression was positively associated 
with WNT signaling, cell cycle, and chromosome segregation pathways.  
Conclusions: ACC has a distinct lncRNA expression profile. LINC00271 is downregulated in 
ACC and appears to be  involved in biologic pathways commonly dysregulated in ACC. 
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Introduction 
 Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy with an annual 
incidence of 0.7–2.0 cases per million people and a five-year overall survival rate ranging from 
32% to 47%).
1,2
 Furthermore, even after complete tumor resection, over half of the patients 
develop recurrent disease.
3
 Patients with locally advanced and metastatic ACC often undergo 
therapy with a regimen including adrenolytic mitotane plus combination chemotherapy with 
etoposide, doxorubicin, and cisplatin. Unfortunately, this regimen has very limited therapeutic 
benefit.
4
 The role of adjuvant therapy for ACC is controversial because of questionable 
therapeutic benefit of current agents and the heterogenous prognosis.
3
 Understanding the 
mechanism behind the  initiation and progression of ACC could help in identifying diagnostic 
and prognostic markers, and therapeutic targets.  
Several genomic studies of ACC have reported a distinct, ACC genome-wide gene 
expression and alteration profiles of micro-RNA expression, methylation, and copy number 
compared with adrenal cortical adenomas (ACAs) and normal adrenal cortex (NAC).
5-10
 These 
studies have led to the molecular classification of ACC that is relevant for predicting prognosis. 
Recently, long, noncoding RNAs (lncRNAs) have been suggested to be dysregulated in ACC.
11
 
LncRNAs are RNA transcripts longer than 200 nucleotides that do not encode protein and are 
localized in the cell nucleus or cytoplasm.
12
 The expression of lncRNAs is more tissue-specific 
than protein-coding genes, and they function as decoys, scaffolds, and enhancer RNAs and are 
involved in chromatin remodeling, as well as transcriptional and post-transcriptional regulation.
13 
To our knowledge, the study by Glover and colleagues has been the only study that has 
investigated lncRNA expression profile in ACCs, ACAs, and NAC.
11
 These investigators 
reported that the greatest number of differentially expressed lncRNAs were between ACAs and 
NAC, with almost 3-fold less lncRNAs being differentially expressed between ACCs and NAC. 
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This finding suggested that changes in lncRNA expression could be an early event in the 
pathogenesis of both ACC and ACAs. This finding, however, is in contrast to the results of 
previous, genome-wide analyses that demonstrated a multistep progression in ACC, with 
increasing genomic changes from NAC to ACA to ACC.
8
 Therefore, to further our knowledge of 
the role of lncRNA in ACCs, we performed lncRNA expression profiling using lncRNA 
microarrays to identify differentially expressed lncRNAs in ACCs compared with NACs and 
ACAs. We also investigated whether lncRNA expression levels were associated with overall 
survival times of ACCs.   
 
Materials and methods 
Tissue samples 
Patient tumor tissues were procured after informed consent for genetic studies on a 
procurement clinical protocol pproved by our  Institutional Review Board(NCT01005654 and 
NCT01348698). The tissues were immediately snap frozen in liquid nitrogen and stored at -80°C. 
For this study, we used 11 ACA samples and nine ACC samples. Five normal NACs were 
obtained at the time of organ donation harvesting. These 25 tissue samples were used for lncRNA 
microarray profiling. In addition to these samples, an additional 10 ACC samples were included 
in the quantitative RT-PCR (qRT-PCR) validation (Table 1). Tumors were classified as benign 
when the Weiss criteria scores were less than 3 (all the benign samples included had a Weiss 
score of 0), and tumors were classified as ACC, when the Weiss criteria scores were more than or 
equal to 3.
14
 Only samples with at least 80% tumor cells were included for analysis. 
 
RNA extraction  
Total RNA was extracted from fresh frozen tissue samples using an RNeasy Mini Kit 
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(Qiagen, Valencia, CA, USA) according to the manufacturer’s instructions. RNA quality was 
assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies, Englewood, CO, USA). 
Only samples with a minimum RNA integrity number of seven were included for analysis. 
 
Microarray profiling  
The ArrayStar Human LncRNA/mRNA Expression Microarray Version 3.0 (ArrayStar, 
Inc., Rockville, MD, USA) used for lncRNA profiling includes 30,586 lncRNA probes and 
26,109 coding transcripts,. RNA labeling, microarray hybridization, slide washing, and scanning 
were performed based on the standard protocols of the ArrayStar. Agilent Feature Extraction 
software (version 11.0.1.1) which was used to analyze acquired array images. The microarray 
specifications and derived data are accessible through National Center for Biotechnology 
Information (NCBI) Gene Expression Omnibus (GEO) accession number GSE124531. 
 
TaqMan real-time quantitative PCR 
RNA was reverse transcribed using the High Capacity, cDNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA, USA). TaqMan qRT-PCR was performed using the 
7900HT, fast, real-time PCR systems (Applied Biosystems). The reaction contained cDNA, 
TaqMan 2×universal PCR master mix, and TaqMan gene expression assays primers (Applied 
Biosystems). LncRNAs were selected for validation based on three criteria: 1) availability of 
validated TaqMan gene expression primer/probe assays, 2) possible role in cancer, and 3) 
magnitude of differential expression. The gene expression assays used were: HOTTIP 
(Hs03649396_m1), CHL1 (Hs04332026_m1), HOXA11-AS1 (Hs_03454334_g1), CRNDE 
(HS04404483_m1), LINC00271 (Hs03657384_m1), FAM211A-AS1 (Hs03678558_g1), TBXAS1 
(Hs01096058_s1) and GAPDH (Hs99999905_m1). 
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Comparative genomic hybridization (CGH) array analysis 
We used our previously published, genome-wide, CGH array data in a cohort of NAC, 
ACA, and ACC.
8
 The LINC100271 site was scanned manually for its copy number status using 
Nexus software.  
 
Statistical and data analysis 
LncRNA expression profiles of ACC samples were compared with NAC and ACA 
samples. The Gaussian linear model was used to calculate P-values, and false discovery rates 
(FDRs) were calculated using the Benjamini-Hochberg method for each lncRNA. LncRNAs with 
a log2 fold change ≥2 and an FDR <0.05 were defined as differentially expressed lncRNAs. 
Differentially expressed lncRNAs were mapped to their associated gene names, and then a gene 
set enrichment analysis (GSEA) was performed on these genes. An in-house. R package, 
OmicPath (v 0.1) was used to perform the GSEA to discover potential KEGG pathway 
associations for each set of differentially expressed lncRNAs. Pathways with a P-value < 0.05 
were considered statistically significant. Survival curves were plotted using the Kaplan-Meier 
methods, and differences in survival rates were determined using the log-rank test. These 
statistical analyses were done with GraphPad Software with  P < 0.05 considered statistically 
significant.  
The ACC cohort from the project database of the Cancer Genome Atlas (TCGA) 
(https://tcga-data.nci.nih.gov/tcga/) which included 79 patients with HOTTIP, CHL1, HOXA11-
AS1, CRNDE, LINC00271, FAM211A-AS1 and TBXAS1 expression data, as well as follow-up 
information, were used to study the prognostic importance of lncRNAs. For the  overall survival 
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analysis, two groups were defined based on the lncRNA expression levels in the primary tumor. 
Those with a lncRNA level ranked in the top half were classified into the high expression group 
and the rest into the low expression group based on the median value.  
 The gene expression profiles of ACC samples deposited in the TCGA project database 
were analyzed to compare expression patterns in tumors with high (n = 39) vs. low LINC100271 
expression (n = 40). The downloaded data consisted of quantified gene expression data that were 
further processed using the DESeq2 package.
15
 The differentialy expressed genes were annotated, 
and GSEA analysis was performed using the clusterProfiler package.
16
  
 
Results 
Differentially expressed lncRNAs in ACC versus NAC 
Unsupervised hierarchical and heat map clustering showed distinct clustering of ACC 
samples compared with NAC and ACA samples (Fig. 1). In these samples, 874 lncRNAs were 
differentially expressed in ACC compared with NAC, of which 409 were upregulated, and 465 
were downregulated. The 874 differentially expressed lncRNAs corresponded to 330 annotated 
lncRNA genes. Among the upregulated lncRNAs, the greatest log2 fold change was 8.5 for an 
unannotated lncRNA gene, and RAD50 was the geratest upregulated, annotated lncRNA gene 
with a log2 fold change of 6.1. Among the downregulated lncRNAs, the greatest log2 fold 
change was 8.3 for an unannotated lncRNA gene and 6.4 for HAND2, the greatest downregulated 
annotated lncRNA gene; of these, 183 differently expressed lncRNAs had established functions 
in cancer development and cancer progression. Selected carcinogenesis-related lncRNAs are 
summarized in Table 2.  
To test the validity of the microarray findings, seven lncRNAs (HOTTIP, CHL1, 
HOXA11-AS1, CRNDE, LINC00271, FAM211A-AS1 and TBXAS1) were selected among the 
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 8 
carcinogenesis-related, differentially expressed lncRNAs, and their expression was analyzed by 
TaqMan qRT-PCR. The validation cohort included 19 ACC samples and 5 NAC samples. 
HOTTIP, HOXA11-AS1 and CRNDE were overexpressed in ACC (P  < 0.05) and confirmed by 
TaqMan qRT-PCR in the validation cohort (P < 0.05; Fig. 2). Expression of LINC00271, 
FAM211A-AS1 and TBXAS1 was downregulated in ACC (P < 0.05) and also by TaqMan qRT-
PCR (P < 0.05) (Fig 2). The microarray result for CHL1 was not confirmed in the validation 
cohort. Upregulated expression of CHL1 was identified in the microarray analysis (P < 0.05) 
while CHL1 was found not to be upregulated by TaqMan qRT-PCR in the validation cohort.  
 
Differentially expressed lncRNAs in ACC versus ACA 
When comparing ACC with ACA, 1076 lncRNAs were differentially expressed , of which 
780 were upregulated, and 296 were downregulated. The 1,076, differentially expressed lncRNAs 
corresponded to 376 annotated lncRNA genes. Among the upregulated lncRNAs, the greatest 
log2 fold change was 8.2 for an unannotated lncRNA and 7.0 for NKAIN4, the greatest 
upregulated annotated lncRNA. Among the downregulated lncRNAs, the greatest log2 fold 
change was 7.1 for an unannotated lncRNA gene and 6.9 for SSTR5, the greatest downregulated 
annotated lncRNA. 
There was overlap in 206 lncRNAs as they were downregulated in ACC compared to 
NAC and in ACC compared to ACA, and 355 lncRNAs overlapped as they were upregulated in 
ACC compared to NAC and ACA (Fig. 3).  
 
Differentially expressed lncRNAs in ACA versus NAC 
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Unsupervised hierarchical and heat map clustering showed that NAC samples clustered 
together with ACA samples (Fig. 1). Only10n lncRNAs were differentially expressed in ACA 
compared with NAC.  
 
Functional pathway analysis 
KEGG pathway analysis of the differentially expressed and annotated lncRNAs in ACC 
compared with NAC and in ACC compared with ACA was performed to understand the biologic 
relevance of these lncRNAs. Twenty-one pathways were significantly enriched in ACC versus 
ACA and 29 pathways were significantly enriched in ACC versus NAC (Tables 3 and 4). Twelve 
of the altered 21 pathways were common to the comparison of ACC versus ACA and ACC 
versus NAC. The KEGG pathways common to both comparisons included ‘Transcriptional 
misregulation in cancer’ and ‘ECM-receptor interaction’. 
 
Prognostic lncRNAs in ACC 
Using the survival data of the ACC TCGA cohort, the prognostic significance of 
HOTTIP, HOXA11-AS1, CRNDE, LINC00271, FAM211A-AS1 and TBXAS1 was analyzed. Only 
LINC00271 expression (Fig. 4A) was found to be associated with prognosis. LINC00271 
expression levels were positively associated with survival time (Fig. 4B). Median survival time 
for the low-LINC00271 expression group (n = 40) was 4.9 years, whereas it was not reached for 
the high-LINC00271 expression group (n = 39) (P < 0.019) (Fig 4C). Student’s t-tests 
demonstrated that LINC00271 expression levels of stage I tumors were greater than those of stage 
IV tumors (P < 0.006). 
 
Identification of LINC00271-associated biologic pathways by Gene Set Enrichment Analysis 
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To identify LINC00271-associated biologic pathways, GSEA was performed using high 
throughput, RNA-sequencing data from the TCGA ACC cohort. Among the GO gene sets, the 
WNT signaling pathway, cell cycle, chromosome segregation, and tissue morphogenesis were 
found to be statistically associated with low LINC00271 expression in the ACC TCGA cohort 
(Fig. 5), suggesting that LINC00271 may be involved in ACC development and/or progression 
through the above cancer-associated signaling pathways. 
 
LINC00271 copy number alterations  
We performed an analysis of the LINC00271 chromosomal locus 6q23.3 using genome-
wide. CGH array data that were generated previously in a cohort of NAC, ACA, and ACC
10
 to 
examine whether the LINC00271 site demonstrated any copy number alterations to explain its 
downregulated expression in ACC. One of 11 NAC samples demonstrated a deletion at 6q23.3, 
whereas 2 of 18 ACA samples demonstrated deletions at 6q23.3, and two other ACA samples 
demonstrated amplifications at 6q23.3. The LINC00271 locus appeared to be the  most unstable 
in ACCs, with 4 of 19 ACC samples demonstrating deletions, and 4 of 19 ACC samples 
demonstrating amplifications of 6q23.3. 
 
Discussion 
This study demonstrated that NAC, ACA, and ACC have distinct lncRNA expression 
profiles, and that LINC00271, 2whhich aappeared to be involved in biologic pathways commonly 
dysregulated in ACC, may be a prognostic marker in ACC.  
When compared with NAC, 874 lncRNAs were differentially expressed in ACC, 1076 
lncRNAs were differentially expressed in ACA compared with ACC, and only t10 lncRNAs were 
differentially expressed in ACA vs. NAC. Previously, Glover and colleagues demonstrated that 
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 11 
the greatest number of differentially expressed lncRNAs in their study was between ACA and 
NAC (2655 lncRNAs), while 956 lncRNAs were differentially expressed between ACC and 
NAC, and 85 lncRNAs were differentially expressed between ACC and ACA.
11
 The data of these 
investiagotrs  suggested that changes in lncRNA expression could be an early part in the 
pathogenesis of both ACC and ACAs.In contrast,  our results are not entirely consistent with their 
findings, because we found only 10lncRNAs that were differentially expressed between ACA and 
NAC.;this finding is in line with the multistep hypothesis in tumorigenesis that is present in most 
human cancers - progressive genetic/genomic alterations increasing/accumulating from NAC to 
ACA to ACC as described previously in our integrated, genome-wide gene expression, gene 
methylation, microRNA expression, and CGH analysis in human samples form NACs, ACAs, 
and ACCs.
8
 The multistep progression from NAC to ACA to ACC is further supported by our 
finding of 296 lncRNAs differentially expressed between ACA versus ACC and 465 lncRNAs 
differentially expressed between ACC vs. NAC. Overall, we found less differently expressed 
lncRNAs in adrenocortical neoplasmscompared to the Glover et al. study
11,
 but we used a more 
stringent cut-off in fold-change to identify differentially expressed lncRNAs, and the NAC 
samples used in our study were not adjacent normal tissue to ACAs. 
In the current study, the TCGA ACC dataset was used to screen for prognostic 
significance of differentially expressed lncRNAs. LINC00271 was found to be associated with 
malignancy; patients with low LINC00271 expression levels survived a significantly lesser time 
than patients with high LINC00271 expression levels. Previously, a statidtifvally lesser 
expression of LINC00271 has been described in invasive breast carcinoma, lung adenocarcinoma, 
kidney renal papillary cell carcinoma, head and neck squamous cell carcinoma, and papillary 
thyroid cancer.
17
 In addition, LINC00271 has been found to be an independent risk factor for 
extrathyroidal extension, lymph node metastasis, advanced tumor stage III/IV, and recurrence in 
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papillary thyroid cancer.
17
 GSEA revealed that genes associated with cell adhesion molecules, the 
TP53 signaling pathway, the JAK/STAT signaling pathway, and the cell cycle were statistically  
enriched in papillary thyroid cancer with a low LINC00271 expression versus papillary thyroid 
cancer with greater LINC00271 expression. We also found that genes associated with cell cycle 
were associated with low LINC00271 expression in the TCGA ACC cohort. Further LINC00271 
expression was positively associated with gthe WNT signaling pathway and chromosome 
segregation which are biologic pathways commonly dysregulated in ACC.
18,19
 Thus, our findings 
and other investigators studies suggest that LINC00271 could contribute to abnormal activation 
of these pathways in a tumor suppressor manner, however, further mechanistic studies are needed 
to test this hypothesis.  
Studies have suggested that genes with causal roles in tumorigenesis are often located in 
chromosomal areas with alterations in copy number.
20,21
 Gene expression levels are directly 
dependent on chromosomal aneuploidies in carcinomas.
22
 The strongest correlations have been 
found between genomic copy number and average, chromosome-wide expression levels, but the 
expression of individual genes has also been associated with genomic copy numbers.
23
 LncRNAs 
expression levels have been positively correlated with alterations in copy number as well.
24,25
 
Therefore, we investigated whether alterations in copy number were present at the LINC00271 
chromosomal locus 6q23.3. This region had the greatest alteration in ACC samples with 21% of 
samples demonstrating amplifications and another 21% demonstrating deletions, while only 11% 
of ACA samples had amplifications and another 11% deletions of 6q23.3. The instability of 
6q23.3 might explain the dysregulated expression of LINC00271 in ACC. 
In conclusion, ACC has a distinct lncRNA expression profile, and LINC00271 
downregulation is appears to be associated with malignancy and may be involved in biologic 
pathways commonly dysregulated in ACC. 
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Tables 
 
Table 1. Clinical features of ACA and ACC patients 
 
 ACA* ACC† included in 
microarray 
ACC in validation 
cohort 
Number of patients 11 9 10 
Age (average ± SD) 46 years ± 19 52 years ± 15 47 years ± 14 
Sex (female/male) 9/2 7/2 6/4
 
Tumor size (average ± SD) 3.8 cm ± 1.8 6.7 cm ± 5.9 5.4 cm ± 2.2 
Functional 55% 44% 30% 
Syndrome‡      
  Adrenal     
  hypercortisolism 
3 4 3 
  Primary     
  hyperaldosteronism 
3 1 0 
  Nonfunctioning 6 4 7 
* ACA, adrenocortical adenoma 
† ACC, adrenocortical carcinoma 
‡ Functional status at initial presentation 
 
 
Table 2. Selected carcinogenesis-related differentially expressed lncRNAs between ACC and NAC 
 
Sequence name Gene symbol Regulation P-value Log2 fold 
change 
Chromosome Relationship 
ENST00000534886 
 
SRRM4  Up 0.001 5.14 Chr12 Intron sense-
overlapping 
ENST00000472494 
 
HOTTIP  Up 9.11 x 10-5 5.05 Chr7 Bidirectional 
ENST00000514846 
 
GRK6  Up 9.92 x 10-6 4.75 Chr5 Natural antisense 
NR_002795 
 
HOXA11  Up 4.61 x 10-5 4.05 Chr7 Bidirectional 
NR_045572 CHL1  Up 3.45 x 10-4 4.16 Chr3 Exon sense-
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 overlapping 
       
ENST00000558031 
 
CRNDE Up 1.30 x 10-5 2.45 Chr16 Intergenic 
ENST00000502941 
 
HAND2  Down 1.52 x 10-7 6.35 Chr4 Bidirectional 
ENST00000450445 
 
BNC2  Down 1.36 x 10-6 5.01 Chr9 Intronic antisense 
ENST00000417354 
 
DNM3  Down 4.46 x 10-6 3.50 Chr1 Intronic antisense 
NR_029394 
 
TBXAS1  Down 2.15 x 10-4 2.51 Chr7 Exon sense-
overlapping 
NR_026805 
 
LINC00271  Down 3.99 x 10-6 2.50 Chr6 Bidirectional 
NR_027158.1 FAM211A-AS1  Down 2.96 x 10-3 2.06 Chr17 Intronic antisense 
 
 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 19 
Table 3. Statistically significant different KEGG pathways in ACC versus ACA 
 
Pathways Genes P-value 
Pathways in cancer 
ADCY2, RALBP1, CSF2RA, DAPK1, FGF13, GSK3B, BIRC5, 
ITGA3, MMP9, PTGER3, SLC2A1, TGFB2, PAX8, RUNX1 1.791e-3 
Vascular smooth muscle contraction KCNMB2, ADCY2, KCNMA1, AVPR1A, PRKCQ, PRKG1 3.251e-3 
Glucagon signaling pathway ADCY2, PRKAG2, PGAM2, PHKA2, SLC2A1 5.823e-3 
Malaria ITGAL, TGFB2, THBS4 7.960e-3 
Transcriptional misregulation in cancer 
HOXA10, HOXA11, MMP9, PAX8, HMGA2, HIST1H3G, 
RUNX1 8.716e-3 
Insulin secretion KCNMB2, ADCY2, KCNMA1, SLC2A1 1.209e-2 
Circadian rhythm ADCY2, PRKG1, PTGER3 1.266 e-2 
Salivary secretion NPAS2, PRKAG2 1.346 e-2 
Cell cycle ADCY2, KCNMA1, LYZ, PRKG1 1.455 e-2 
Colorectal cancer E2F5, GSK3B, MAD2L1, RBL2, TGFB2 1.522 e-2 
FoxO signaling pathway GSK3B, BIRC5, TGFB2 1.786 e-2 
Glycolysis / Gluconeogenesis S1PR1, PRKAG2, RBL2, BNIP3, TGFB2 2.149 e-2 
Ubiquitin mediated proteolysis PGAM2, ADPGK, FBP2 2.307 e-2 
Adipocytokine signaling pathway UBE2S, UBE2D4, SIAH1, UBE2G2, ITCH 2.367 e-2 
Signaling pathways regulating pluripotency of stem 
cells PRKAG2, PRKCQ, SLC2A1 2.661 e-2 
Bladder cancer ESRRB, GSK3B, PAX6, POU5F1B, PCGF1 2.762 e-2 
Insulin resistance DAPK1, MMP9 2.841 e-2 
RNA degradation GSK3B, PRKAG2, PRKCQ, SLC2A1 3.180 e-2 
ECM-receptor interaction LSM1, EXOSC10, BTG1 3.605 e-2 
Hypertrophic cardiomyopathy (HCM) SV2C, ITGA3, THBS4 4.385e-2 
Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type 
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Table 4. Statistically significantly different KEGG pathways in ACC versus NAC  
 
Pathways Genes P-value 
ECM-receptor interaction COL6A2, SV2C, ITGA3, ITGA9, THBS2 5.329e-4 
Circadian rhythm NPAS2, PRKAG2, BHLHE40 5.596e-4 
Vascular smooth muscle contraction 
MRVI1, KCNMA1, AVPR1A, PRKACB, PRKCQ, 
PRKG1 7.222e-4 
Adipocytokine signaling pathway IKBKB, PRKAG2, PRKCQ, SLC2A1 1.759e-3 
Transcriptional misregulation in cancer 
HOXA11, MEIS1, MMP9, UTY, PAX8, HMGA2, 
HIST1H3G 1.785e-3 
Cocaine addiction GRIN3B, GRM3, PRKACB 3.175e-3 
Salivary secretion KCNMA1, LYZ, PRKACB, PRKG1 5.0121e-3 
Glucagon signaling pathway PRKAG2, PGAM2, PRKACB, SLC2A1 8.511e-3 
Glycolysis / Gluconeogenesis ADH1A, PGAM2, ADPGK 9.687e-3 
Insulin resistance IKBKB, PRKAG2, PRKCQ, SLC2A1 1.161e-2 
Nicotine addiction CHRNA4, GRIN3B 1.345e-2 
Proteasome PSMA3, PSMD7 1.740e-2 
Platelet activation LYN, PRKACB, PRKG1, TBXAS1 1.817e-2 
Hypertrophic cardiomyopathy (HCM) ITGA3, ITGA9, PRKAG2 1.998e-2 
Hedgehog signaling pathway CDON, PRKACB 2.074e-2 
Endocrine and other factor-regulated calcium reabsorption DNM3, PRKACB 2.074e-2 
Insulin secretion KCNMA1, PRKACB, SLC2A1 2.161e-2 
Neuroactive ligand-receptor interaction 
CHRNA4, GRIN3B, GRM3, AVPR1A, RXFP1, SSTR5, 
THRB 2.227e-2 
Dilated cardiomyopathy ITGA3, ITGA9, PRKACB 2.602e-2 
Morphine addiction GRK6, PDE4D, PRKACB 2.697e-2 
NF-kappa B signaling pathway IKBKB, LYN, PRKCQ 2.891e-2 
Circadian entrainment PRKACB, PRKG1, CACNA1H 3.094e-2 
Regulation of lipolysis in adipocytes PRKACB, PRKG1 3.273e-2 
Long-term depression LYN, PRKG1 3.900e-2 
Focal adhesion COL6A2, ITGA3, ITGA9, PAK3, THBS2 4.064e-2 
T cell receptor signaling pathway IKBKB, PAK3, PRKCQ 4.110e-2 
Longevity regulating pathway – multiple species PRKAG2, PRKACB 4.584e-2 
Renin secretion KCNMA1, PRKACB 4.584e-2 
Renal cell carcinoma PAK3, SLC2A1 4.946e-2 
Note Pathways common to the comparison of ACC versus ACA and ACC versus NAC are written in bold type 
 
 
 
 
 
 
 
 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 21 
Figure legends 
 
Fig 1. Unsupervised hierarchical clustering and heat map of lncRNA expression between 
adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA), and normal adrenal cortex 
(NAC). Each column represents a sample, and each row represents a lncRNA. High relative 
expression is indicated in yellow and low relative expression in red. 
 
Fig 2. TaqMan qRT-PCR validation of lncRNA microarray analysis. Fold-change in comparison 
of ACCversusNAC, *P < 0.05.  
 
Fig 3. Venn diagram showing the number of overlapping up- or downregulated lncRNAs in the 
different comparisons.  
 
Fig 4. LINC00271 expression and prognosis. A, Distribution of LINC00271 expression of ACC 
samples from the TCGA dataset. Red points were defined as low-LINC00271 expression group 
and black points were defined as high-LINC00271 expression group. B, LINC00271 expression is 
positively correlated to survival time (Pearson correlation coefficient = 0.50). C, Kaplan-Meier 
plot of overall survival in the TCGA the ACCcohort is shown according to LINC00271 
expression level (low vs. high).  
 
Fig 5. LINC00271-associated biologic signaling pathways. Based on the TCGA dataset, GSEA 
showed that genes associated with WNT signaling pathway, cell cycle, chromosome segregation 
and tissue morphogenesis were statistically  enriched in lower LINC00271 versus greater 
LINC00271 expressing ACCs. FDR, false discovery rate; NES, normalized enrichment score. 
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Discussion of Paper Number 22  
 
ADRENOCORTICAL TUMORS HAVE A DISTINCT 
LONG NON-CODING RNA EXPRESSION PROFILE AND 
LINC00271 IS A PROGNOSTIC MARKER IN 
ADRENOCORTICAL CARCINOMA  
  
DISCUSSANT 
  
DR. XAVIER KEUTGEN (Chicago, IL):  
First of all, did you look at LINC00271 expression 
in your cell lines? 
 
CLOSING DISCUSSANT 
 
DR. FLORYNE O. BUISHAND:  Yes, we also 
looked at LINC00271 expression in cell lines, and 
it is expressed.  We also tried to knock it down; 
Unfortunately, that did not work. 
 
 
Discussion
Click here to view linked References
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DISCUSSANT 
  
DR. XAVIER KEUTGEN (Chicago, IL):  
That would have been my next question because that 
may help you find out if it truly has an impact 
on the Wnt pathway, but it's basically 
downregulated as far as you could tell.  Good. 
Then the second question is, what do we 
do with this?  Should this change our diagnostic 
or therapeutic approach?   
CLOSING DISCUSSANT 
 
DR. FLORYNE O. BUISHAND:  Obviously, 
the study is not powered adequately to say this 
is really an excellent prognostic factor.  So it 
needs more study before we can actually 
incorporate it in the current treatment 
protocols.  
 
DISCUSSANT 
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DR. MARK COHEN (Ann Arbor, MI):  How 
confident are you that this is really a marker for 
malignancy given that only 4 out of 19 of your 
cancers showed alterations in the long non-coding 
RNA and a certain percentage of adenomas do as 
well.  
 
CLOSING DISCUSSANT 
 
DR. FLORYNE O. BUISHAND:  Obviously, 
we only had to look at the copy number status to 
see if we could find an explanation for the 
dysregulated expression.  Those numbers are low, 
so we cannot be certain that it is really due to 
dysregulated copy number status.  But I do think 
that we have shown with this work that LINC00271 
expression is correlated and associated with 
malignancy and survival.  
 
DISCUSSANT 
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DR. EMAD KANDIL (New Orleans, LA):  The 
first question is about the design of the study.  
You decided to do the microRNA-seq on your 
specimens and then went back to the TCGA database.  
Usually, you do the bioinformatic analysis in the 
TCGA database, identify a panel, and then go back 
to your specimens and try to find this.  I wonder 
why you decided to do it the other way around.   
You had the seven genes or seven LINC 
RNAs, and then you decided to just focus on the 
LINC00271.  I wonder how that happened.  Why not 
a panel?  Specifically, I think if you are 
looking at prognosis, the panel would be more 
informative than just trying to focus on one. 
 
CLOSING DISCUSSANT 
 
DR. FLORYNE O. BUISHAND:  To address 
your first question, I think we could have gone 
back from the high throughput analysis that we did 
with the microarray.  We started with that, and 
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then went on to have a look at the TCGA database, 
and we have could have gone back to our own 
samples.  But, unfortunately, I don't think that 
we have enough samples to actually make stronger 
conclusions than using the TCGA data set.   
Regarding the second part of your 
question, I think I forgot to mention that we did 
have a look at all those six validated LINC RNAs, 
whether they had prognostic significance, and we 
only found prognostic significance for 
LINC00271.  So the other five did not have any 
prognostic significance.  
 
DISCUSSANT 
 
DR. MICHAEL DEMEURE (Newport Beach, 
CA):  TCGA data are actually slanted toward early 
resectable lesions.  Those are the operative 
samples, for the most part.  So as you added it 
to your multi-step progression, was there a 
difference between localized and metastatic 
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adrenal cancers in terms of the long non-coding 
RNA? 
I'm interested in if you are 
hypothesizing that you are seeing progression 
from adenoma to carcinoma.  Given the TCGA is 
really slanted toward resected operative 
samples, and thus by definition earlier stage 
tumors, do you have a cohort of stage 4 disease?  
And could you link continuation of that 
progression with the long non-coding RNA?  
 
CLOSING DISCUSSANT 
 
DR. FLORYNE O. BUISHAND:  Thank you so 
much for the excellent suggestion.  Basically, 
we concluded on our limited sample set that there 
is a stepwise progression, and it would be really 
good to follow up on that finding.  But you are 
correct, we cannot really elaborate on that, 
given the fact that the TCGA database only has 
resectable samples.  
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Adrenocortical carcinoma (ACC) has a distinct lncRNA expression profile and LINC00271 is a prognostic 
marker in ACC. The importance of this finding is that LINC00271 may serve as a potential predictor for 
poor clinical outcomes. 
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